MindHYVE.ai Partners with ICS Pakistan and NEI Pakistan to Revolutionize Nursing Education with AI-Powered ArthurAI
Pakistan faces a critical shortage of nursing professionals, with approximately 0.47 nurses and midwives per 1,000 people—significantly below the World Health Organization's recommended minimum of 2.5 per 1,000 (World Bank, 2019; International Labour Organization). In clinical settings, the ideal nurse-to-patient ratio is 3 nurses for every 10 patients, yet many facilities operate with fewer, affecting care quality and increasing workforce strain (Pakistan Nursing Council).
ArthurAI™ licenses will initially target 2,000 nursing students within the first year, scaling to 10,000 nursing students within two years. Over the longer term, MindHYVE.ai aims to empower 80,000 nurses nationwide with ArthurAI™, positioning this collaboration as a transformative force in Pakistan's nursing education and healthcare workforce development. Bill Faruki, CEO of Mindhyve.ai stated " Our partnerships with ICS and NEI reflect a shared commitment to harness AI's power in shaping the future of healthcare education in Pakistan. ArthurAI™ will empower both students and educators to achieve unprecedented levels of personalization, efficiency, and academic success." Mohammad Aurangzeb Nadeem, Executive Director of ICS and NEI added "We are excited to pioneer AI-driven transformation in nursing education. This unified effort will strengthen our academic programs, enhance student outcomes, and support Pakistan's healthcare sector with skilled nursing professionals ready for tomorrow's challenges."
About ICS & NEI Pakistan
ICS, a leading private-sector institution, hosts and delivers the Post-RN BSN nursing program for Khyber Medical University, focusing on inclusive education and AI-enhanced curriculum development. NEI, a specialized healthcare education institute, advances nursing excellence and digital innovation by embedding ArthurAI™ as a virtual assistant within its Post-RN BSN program.
About MindHYVE.ai™
MindHYVE.ai™ is redefining the boundaries of intelligence by engineering autonomous systems and deploying domain-specific AGI agents across real-world sectors. Powered by the Ava-Fusion™ large reasoning model and architected for agent coordination, swarm intelligence, and adaptive autonomy, MindHYVE's technology stack is revolutionizing law, medicine, finance, education, and governance.
With operations in North America, Asia, and in Africa, MindHYVE.ai™ is on a mission to democratize access to transformative intelligence and architect the infrastructure for post-scarcity economies. Backed by HYVE Labs, the company continues to shape the future of agentic systems on a global scale.
Media Contact
Marc Ortiz
Email: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
a day ago
- CTV News
Lilly signs US$1.3 billion deal with Superluminal to discover obesity medicines using AI
A sign for Eli Lilly & Co. stands outside their corporate headquarters in Indianapolis. (AP Photo/Darron Cummings, File) Eli Lilly has signed a deal worth US$1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases. Lilly currently dominates the obesity treatment market, estimated to be worth $150 billion by the next decade, and is trying to strengthen its foothold in the space through the development of next-generation drugs, acquisitions and partnerships. The deal gives Lilly exclusive rights to develop and commercialize drug candidates discovered using Superluminal's proprietary AI-driven platform targeting G-protein-coupled receptors (GPCR) - a class of proteins that can influence physiological processes including metabolism, cell growth and immune responses - the drug developer said on Thursday. Drugmakers including Danish rival Novo Nordisk are exploring potential GPCR targets to develop oral small-molecule drugs for obesity. 'GPCRs have established themselves as very important targets in the obesity and cardiometabolic landscape, but we're at the very early stages of exploration of the target class,' Superluminal CEO Cony D'Cruz told Reuters. Novo struck a $2.2 billion deal with U.S. biotech Septerna in May to develop small-molecule therapies directed at select GPCR targets. Lilly has been capitalizing on the overwhelming popularity of the GLP-1 class of medicines, including its blockbuster drug Zepbound as well as Novo's Wegovy. It is also developing a keenly watched oral GLP-1 drug, orforglipron, which has failed to meet investor expectations. The drugmaker teamed up with Hong Kong-listed biotech Laekna last year to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle. As part of the deal, Superluminal is eligible to receive upfront and milestone payments, an equity investment as well as tiered royalties on net sales, the company said. Boston-based startup Superluminal is developing a wholly owned lead candidate targeting a protein called melanocortin 4 receptor to treat certain rare, genetic forms of obesity and is expected to begin human trials by fourth quarter next year. The lead candidate is not part of the deal with Lilly. Superluminal is backed by investors including RA Capital Management, Insight Partners and NVentures, NVIDIA's venture capital arm. (Reporting by Mariam Sunny in Bengaluru; Editing by Pooja Desai)
Winnipeg Free Press
2 days ago
- Winnipeg Free Press
A look at CP's coverage plans for back to school 2025
Parents and students prepping for another year of classes do so amid challenges new and old: emerging tech, rising costs, infection fears, divisive politics and bullying. Not to mention the seemingly constant dilemma of what to put in your kids' lunchbox. Here's a look at the features and explainers planned by The Canadian Press as families gear up for a new school year. Stories and approximate run dates: Harvard-Canadians: The Trump administration's decision to bar international students from Harvard earlier this year left Canadian students who had hopes for completing their Ivy League education at the Massachusetts school anxious about their futures. We check back in with them as the school year approaches. By Cassidy McMackon. Moves Aug 15. Measles-Vaccine-Schedule: Some provinces give the second dose of the measles vaccine at 18 months, while others don't give the second dose until age four. This means that some kids in Ontario, for instance, might be entering school without being fully protected amid the province's outbreak that has sickened more than 2,000 people. Here's what the experts say parents should know about the different schedule, and why they should consider fully vaccinating their toddlers before September. By Hannah Alberga. Aug. 18. Cda-Universities-AI: A look at how Canadian universities are navigating the use of artificial intelligence by students and teachers — and how schools are trying to ensure the technology improves learning outcomes rather than worsening them. Maan Alhmidi. Aug. 19 Teaching-Influencing: Gen Z increasingly sees influencer marketing as a viable career choice and several Canadian school are pitching courses teaching them to become just that— what skills to they teach, and how popular are they? By Nicole Thompson. Moves Aug. 21. Teaching-Climate-Change: Teachers share how they use major weather events to help explain the impact of climate change to children, but face restrictions with the current curriculum. By Cassidy McMackon. Moves: Aug. 22 Student-Woes-Vignettes: The challenges facing post-secondary students have been amplified by a cost-of-living crisis, fractured political climate and increasing social isolation driven in part by AI and smartphone technology. We speak to some of them about their lives. By Rianna Lim. Aug. 24 Young-Influencers: A look at how some young influencers plan to navigate their studies with their plans to continue posting about their lives online — especially those whose profiles blew up over the summer. By Vanessa Tibeiro. Moves Aug. 25. Financial-Literacy: Recent data shows Gen Z is better at saving than Millennials, with many saying they learn about finances online. A look at how even those who are minors are taught about money, and what's behind the increased awareness as young people prepare to enter into a cost-of-living crisis. By Natasha Baldin. Aug. 26 School-Lunches: Many parents who aren't Meghan Markle dread planning school lunches. How to master package-less, nut-free, whole-food meals to satiate picky eaters in a rush. By Cassandra Szklarski. Aug. 27 Medical-School-Students: We talk to first-year medical students who are the first in their family to pursue a career as a doctor and have faced racial, economic or social barriers to get there. By Nicole Ireland. Aug. 30 Bullying-Prep: Tips on how Black, racialized and neurodiverse youth can navigate social and school situations safely. By Cassandra Szklarski/Nicole Thompson. Sept. 2
Globe and Mail
2 days ago
- Globe and Mail
Carlsmed Inc. to Report Second Quarter 2025 Financial Results on August 28, 2025
CARLSBAD, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its second quarter 2025 financial results after market close on Thursday, August 28, 2025. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the start of the conference call. Event Date: Thursday, August 28, 2025 Time: 1:30 PM Pacific Time Participant Registration: A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website here. About Carlsmed Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. Investor Relations IR@ Media
